Nexalin Technology (NXL) Operating Leases (2021 - 2023)

Nexalin Technology (NXL) recorded quarterly Operating Leases of $43026.0 in Q1 2023, up 864.06% quarter-over-quarter from $4463.0 in Q4 2022.

Nexalin Technology (NXL) Operating Leases (2021 - 2023) Analysis & Trends

Nexalin Technology's Operating Leases history runs 3 years deep, the most recent figure standing at $43026.0 for Q1 2023.

  • In Q1 2023, Operating Leases changed N/A year-over-year to $43026.0; the TTM figure through Mar 2023 stood at $43026.0 (changed N/A YoY), while the FY2022 annual figure was $4463.0, down 87.93% from the prior year.
  • Operating Leases was $43026.0 for Q1 2023 at Nexalin Technology, up from $4463.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $43026.0 in Q1 2023 to a low of $4463.0 in Q4 2022.
  • Historically, Operating Leases has averaged $25524.0 across 3 years, with a median of $27303.5 in 2021.
  • Biggest YoY gain for Operating Leases was 87.93% in 2022; the steepest drop was 87.93% in 2022.
  • A 3-year view of Operating Leases shows it stood at $36973.0 in 2021, then plunged by 87.93% to $4463.0 in 2022, then jumped by 864.06% to $43026.0 in 2023.
  • The last three Operating Leases figures came in at $43026.0 (Q1 2023), $4463.0 (Q4 2022), and $17634.0 (Q3 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 Nexalin Technology 7.82 Mn 5.11 Mn 13,133.00

Historic Data

Download Data
DateValue
Mar 31, 2023 43,026.00
Dec 31, 2022 4,463.00
Sep 30, 2022 17,634.00
Dec 31, 2021 36,973.00